200-year-old condom etched with erotic art makes museum debut
The Rijksmuseum described the condom, thought to be crafted around 1830 from a sheep's appendix, as a depiction of "both the playful and the serious side of sexual health."
The unusual artefact is showcased in the "Safe Sex?" exhibition, which opened on Tuesday and explores the realities of 19th-century sex work. The condom, potentially a souvenir from a brothel, features an erotic image of a nun and three clergymen.
The phrase 'This is my choice' is written along the sheath in French. According to the museum, this is a reference to the Pierre-Auguste Renoir painting 'The Judgment of Paris,' which depicts the Trojan prince Paris judging a beauty contest between three goddesses.
The condom is on display until the end of November.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
12 minutes ago
- Daily Mail
Shower gel advert banned for depicting black skin as 'problematic' and white skin as 'superior' by advertising watchdog
A shower gel advert has been banned for depicting black skin as 'problematic' and white skin as 'superior', the advertising watchdog has said. The Advertising Standards Authority (ASA) banned the ad after investigating complaints that it perpetuated a 'negative and offensive racial stereotype'. The Sanex shower gel ad, broadcast in June, depicted a black woman with red scratch marks and another covered with a cracked clay-like material. Over this, a voiceover said: 'To those who might scratch day and night. To those whose skin will feel dried out even by water.' Over scenes of a white woman the ad stated: 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24 hour hydration feel.' The ad ended with on-screen text and the voiceover adding: 'Relief could be as simple as a shower.' Colgate-Palmolive, which owns the Sanex brand, argued the depiction of diverse models in the ad was shown in a 'before and after' scenario to demonstrate their product was suitable for all, rather than as a comparison based on race or ethnicity. On that basis, it believed the ad did not perpetuate negative racial stereotypes and was not likely to cause serious or widespread offence. Clearcast, which approves or rejects ads for television broadcast, said the ad did not perpetuate negative racial stereotypes and instead demonstrated the product's inclusivity. The agency said one model with darker skin was depicted in a 'stylised and unrealistic way' to demonstrate dryness, but her skin tone was otherwise not a focal point. However the ASA said the use of different skin colours created a juxtaposition of black skin shown as itchy and dry in the 'before' scenes, and white skin shown as smoother in the 'after' scenes. The watchdog said: 'The ad was therefore structured in such a way that it was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved. 'We considered that could be interpreted as suggesting that white skin was superior to black skin.' The ASA added: 'Although we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers, we considered that the ad was likely to reinforce the negative and offensive racial stereotype that black skin was problematic and that white skin was superior. 'We concluded that the ad included a racial stereotype and was therefore likely to cause serious offence.' Colgate-Palmolive was approached for comment.
The Independent
13 minutes ago
- The Independent
Diabetes patients could be offered weight loss jabs sooner in major shake-up
People with type 2 diabetes in England could be offered treatments, including weight loss jabs, sooner in the biggest shake-up of care in a decade. New draft guidance from the National Institute for Health and Care Excellence (Nice) recommends a shift from a one-size-fits-all approach of starting everyone on the same medication to more personalised care that aims to prevent complications like heart failure and heart attacks. Newer type 2 diabetes drugs, known as SGLT-2 inhibitors, would be made a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as control blood sugar, Nice said. It is estimated that the change could save almost 22,000 lives once uptake reaches 90 per cent of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Daily Mail
14 minutes ago
- Daily Mail
Natalie Portman becomes frontrunner to play Sinead O'Connor in biopic about her life
Natalie Portman is reportedly the frontrunner to play Sinead O'Connor in a biopic about her life. The Irish Grammy-winning singer passed away from natural causes at the age of 56 in July 2023 - just 18 months after the death of her son. In the days leading up to her tragic passing, Sinead was rumoured to be deep in discussions for a biopic inspired by her life. Now, Natalie is said to be in the running to take on the role, with a source telling The Sun: 'Natalie is the actress the filmmakers want to play Sinéad. 'They think she is the spit of Sinéad in terms of her physicality but as an actress, they know she has the strength and power to do justice to Sinéad.' Earlier this week, Variety reported that Irish production company ie: entertainment, which executive produced the O'Connor documentary is behind the film. Daily Mail has contacted Natalie Portman's representative for comment. The film was previously have said to have been based on her June 2021 autobiography Rememberings. According to insiders in 2023, the iconic artist had been considering a star-studded cast for the pivotal role, which included Hollywood's Demi Moore. Irish actress Saoirse Ronan was also in the running to play an earlier stage in Sinead's life as well as Niamh Algar. A source explained that when exploring initial concepts for the film, Sinead liked the idea of a 'triptych approach' and envisioned a film that would spotlight three distinct actresses. They added that this creative direction playfully alluded to the Catholic Church's symbolic trinity of father, son, and the Holy Ghost and added a touch of satire into the narrative. An inquest into Sinead son Shane's death in November said the pair had a 'complex and turbulent' relationship but were also very close and 'in some way dependent on each other throughout their lives.' The body of Shane O'Connor, 17, was found in a secluded area at the back of a housing estate outside Bray, Co Wicklow on January 7, 2022 less than 24 hours after he was reported missing from Tallaght University Hospital in Dublin. The Nothing Compares 2 U singer, who formally identified her son's body to gardaí, died suddenly herself from natural causes just 18 months later in London. At the time of Shane's death, he was due to be under supervised 24/7 one-to-one care. A sitting of Dublin District Coroner's Court heard the teenager had been brought to the emergency department by his mother on December 29, 2021 after a drug overdose, in what was believed to be an attempted suicide. Sinead O'Connor's father Sean described how his daughter and Shane were 'very close.' 'They loved each other madly,' he observed. Mr O'Connor outlined how the singer was also suffering mental health issues around the same time of her son's death.
